SEC Clears Hemopurifier Device for Cancer Study in Indian Patients
Written By : Dr. Kamal Kant Kohli
Published On 2025-06-26 14:20 GMT | Update On 2025-06-26 14:20 GMT
Advertisement
New Delhi: In a step toward advancing medical device-based cancer care, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organisation (CDSCO) has granted permission to conduct a pilot clinical investigation of the Hemopurifier device in India.
The proposal, submitted by Qualtran Consulting, was reviewed during the 19th SEC (Oncology) meeting held on 5th June 2025 at CDSCO headquarters, New Delhi.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.